Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Array BioPharma Jumped 31% in January

By Cory Renauer – Updated Apr 19, 2019 at 10:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors had more than one reason to feel good about Array BioPharma last month.

What happened

Shares of Array BioPharma (ARRY), an oncology-focused biopharmaceutical company, rose 31% in January, according to data from S&P Global Market Intelligence. Last month, Eli Lilly (LLY -2.02%) agreed to pay $8 billion for a few drugs that Array still owns a piece of. Also, a combination therapy Array already markets took a big step toward an important label expansion.

So what 

The new year kicked off with Eli Lilly agreeing to acquire Loxo Oncology (LOXO) for $8 billion in cash. Lilly was drawn to the highly specific kinase inhibitors that Loxo acquired from Array Biopharma. 

Man in a suit flying with a cartoon jetpack, next to an upward-sloping arrow indicating a rising stock.

Image source: Getty Images.

Lilly's interest in drugs Array discovered wasn't the only good news last month. We also learned that Array's combination of Braftovi plus Mektovi for melanoma patients with BRAF mutations could become part of a triplet therapy for patients with advanced-stage colorectal cancer. Braftovi plus Mektovi added to Erbitux extended median overall survival for these patients to 15.3 months. We don't have a comparison group measure the triplet against, but we know a majority of similar patients don't survive more than six months following standard care.

Check out the latest Array BioPharma earnings call transcript.

Now what

According to Array, the FDA appears willing to grant the triplet an accelerated approval based on the overall response rate and durability of those responses. Array anticipates response rate results during an interim analysis scheduled for the first half of 2019. If the results are positive, an approval to treat colorectal cancer patients could happen in 2020.

Array's entitled to another $635 million in commercialization milestones from Eli Lilly, plus royalties on any sales of partnered drug candidates. With Lilly's muscle behind Vitrakvi and LOXO-292, Array has a much better chance to receive those milestone payments and significant royalties. With a handful of growing revenue streams, Array looks like a top biotech stock to buy.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
ARRY
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$323.35 (-2.02%) $-6.66
Loxo Oncology Stock Quote
Loxo Oncology
LOXO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.